Previous studies demonstrated that therapeutic application of recombinant mOSM markedly improved cardiac performance and dramatically increased survival after infarction, whereas strains with OSMR deletion showed a reduced ejection fraction and high mortality [12, 27, 28]. This evidence concerns the gene OSMR and infarction.